Low dose dexmedetomidine good enough to relieve emergence agitation in children: Study
Lower dosage of dexmedetomidine with sevoflurane anesthesia showed equal effectiveness to relieve emergence agitation (EA) without the need for a larger dose in general post-operative period, reveals a new study. The study was designed by the team of anesthesiologist from Pondicherry to compare the different doses of dexmedetomidine including pain and hemodynamic assessment during the postoperative period and was published in the Indian Journal of Anesthesia on 23 July 2021.
Sevoflurane, the commonly used pediatric inhalation anesthesia is strongly associated to EA due to its solubility and rapid recovery. Dexmedetomidine is a proven agent to reduce Post-operative EA with Sevoflurane and also reduces the need for additional anesthetic agents.
The study included 80 children (40 in each group) of 5 to 14 years, undergoing adenotonsillectomy or tonsillectomy under sevoflurane anesthesia. They were randomly divided into Group A who received 0.3 µg/kg/h of dexmedetomidine, and Group B who received 0.5 µg/kg/h of dexmedetomidine after a bolus dose.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.